WallStreetZenWallStreetZen

NASDAQ: LEXX
Lexaria Bioscience Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for LEXX

Based on 1 analyst offering 12 month price targets for Lexaria Bioscience Corp

Min Forecast
$7.00+340.25%
Avg Forecast
$7.00+340.25%
Max Forecast
$7.00+340.25%

Should I buy or sell LEXX stock?

Based on 1 analyst offering ratings for Lexaria Bioscience Corp.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their LEXX stock forecasts and price targets.

LEXX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-01-24

1 of 1

Forecast return on equity

Is LEXX forecast to generate an efficient return?

Company
-93.39%
Industry
80.75%
Market
61.89%
LEXX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LEXX forecast to generate an efficient return on assets?

Company
-76.89%
Industry
22.1%
LEXX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LEXX earnings per share forecast

What is LEXX's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$0.59
Avg 2 year Forecast
-$0.46
Avg 3 year Forecast
-$0.38

LEXX revenue forecast

What is LEXX's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$595.0k+13.13%
Avg 2 year Forecast
$785.0k+49.26%
Avg 3 year Forecast
$1.4M+166.2%
LEXX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LEXX revenue growth forecast

How is LEXX forecast to perform vs Biotechnology companies and vs the US market?

Company
31.28%
Industry
145.84%
Market
10.58%
LEXX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LEXX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LEXX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LEXX$1.59$7.00+340.25%Buy
VYNE$1.84$6.88+273.64%Strong Buy
PYPD$2.75$10.50+281.82%Buy
GDTC$2.40N/AN/A
DOMH$4.53N/AN/A
View Top Biotech Stocks

Lexaria Bioscience Stock Forecast FAQ

Is Lexaria Bioscience Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: LEXX) stock is to Buy LEXX stock.

Out of 1 analyst, 0 (0%) are recommending LEXX as a Strong Buy, 1 (100%) are recommending LEXX as a Buy, 0 (0%) are recommending LEXX as a Hold, 0 (0%) are recommending LEXX as a Sell, and 0 (0%) are recommending LEXX as a Strong Sell.

If you're new to stock investing, here's how to buy Lexaria Bioscience stock.

What is LEXX's earnings growth forecast for 2025-2027?

(NASDAQ: LEXX) Lexaria Bioscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 17.83%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 23.31%.

Lexaria Bioscience's earnings in 2025 is -$9,383,394.On average, 2 Wall Street analysts forecast LEXX's earnings for 2025 to be -$10,272,120, with the lowest LEXX earnings forecast at -$10,535,507, and the highest LEXX earnings forecast at -$10,008,732. On average, 2 Wall Street analysts forecast LEXX's earnings for 2026 to be -$8,077,222, with the lowest LEXX earnings forecast at -$8,252,814, and the highest LEXX earnings forecast at -$7,901,631.

In 2027, LEXX is forecast to generate -$6,672,488 in earnings, with the lowest earnings forecast at -$6,672,488 and the highest earnings forecast at -$6,672,488.

What is LEXX's revenue growth forecast for 2025-2027?

(NASDAQ: LEXX) Lexaria Bioscience's forecast annual revenue growth rate of 31.28% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 145.84%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.58%.

Lexaria Bioscience's revenue in 2025 is $525,923.On average, 2 Wall Street analysts forecast LEXX's revenue for 2025 to be $10,447,712, with the lowest LEXX revenue forecast at $8,428,406, and the highest LEXX revenue forecast at $12,467,017. On average, 2 Wall Street analysts forecast LEXX's revenue for 2026 to be $13,783,956, with the lowest LEXX revenue forecast at $7,023,672, and the highest LEXX revenue forecast at $20,544,239.

In 2027, LEXX is forecast to generate $24,582,851 in revenue, with the lowest revenue forecast at $24,582,851 and the highest revenue forecast at $24,582,851.

What is LEXX's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: LEXX) forecast ROA is -76.89%, which is lower than the forecast US Biotechnology industry average of 22.1%.

What is LEXX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year LEXX price target, the average LEXX price target is $7.00, with the highest LEXX stock price forecast at $7.00 and the lowest LEXX stock price forecast at $7.00.

The Wall Street analyst predicted that Lexaria Bioscience's share price could reach $7.00 by Jan 24, 2026. The average Lexaria Bioscience stock price prediction forecasts a potential upside of 340.25% from the current LEXX share price of $1.59.

What is LEXX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: LEXX) Lexaria Bioscience's current Earnings Per Share (EPS) is -$0.59. On average, analysts forecast that LEXX's EPS will be -$0.59 for 2025, with the lowest EPS forecast at -$0.60, and the highest EPS forecast at -$0.57. On average, analysts forecast that LEXX's EPS will be -$0.46 for 2026, with the lowest EPS forecast at -$0.47, and the highest EPS forecast at -$0.45. In 2027, LEXX's EPS is forecast to hit -$0.38 (min: -$0.38, max: -$0.38).

What is LEXX's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: LEXX) forecast ROE is -93.39%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.